MedTrace Logo

Renal Denervation by Allegro System in Patients With Resistant Hypertension

NCT01874470 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2016-10-20

No results posted yet for this study

Summary

The purpose of ALLEGRO-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with resistant hypertension by using Allegro renal denervation system

Conditions

  • Renal Denervation
  • Resistant Hypertension
  • Standard Medication

Interventions

DEVICE

renal denervation

OTHER

standard medication

Sponsors & Collaborators

  • Shanghai AngioCare Medical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874470 on ClinicalTrials.gov